Dataset from GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

The purpose of this study was to test a potential new kind of anti-cancer treatment, called PRAME immunotherapy in resected patients with lung cancer. As of 18 July 2014, the recruitment was stopped prematurely and the study was unblinded. Only patients on active treatment will have the option to continue in the study. Patients randomised to the Placebo group were withdrawn. There will no longer be an active follow-up of patients after discontinuation or completion of the treatment. The study will end 30 days after the last dose will be administered. As a result, primary and secondary objectives will not be assessed as planned. All clinical and safety data collected in the study will be analysed descriptively. For each biological sample already collected in the scope of this study and not tested yet, testing will not be performed by default, except if a scientific rationale remains relevant despite the premature termination of the study.